The soluble guanylate cyclase stimulator riociguat ameliorates pulmonary hypertension induced by hypoxia and SU5416 in rats

PLoS ONE

Volumn 7, Issue 8, 2012, Pages

  Lang, Michaela ^a   Kojonazarov, Baktybek ^a   Tian, Xia ^a   Kalymbetov, Anuar ^a   Weissmann, Norbert ^a   Grimminger, Friedrich ^a   Kretschmer, Axel ^b   Stasch, Johannes Peter ^b   Seeger, Werner ^a,c   Ghofrani, Hossein Ardeschir ^a   Schermuly, Ralph Theo ^a,c  

^a JUSTUS LIEBIG UNIVERSITY GIESSEN   (Germany)

^b BAYER PHARMA AG   (Germany)

^c MAX PLANCK INSTITUTE FOR HEART AND LUNG RESEARCH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN; CYCLIC GMP; GUANYLATE CYCLASE; GUANYLATE CYCLASE ACTIVATOR; NITRIC OXIDE; PHOSPHODIESTERASE V; RIOCIGUAT; SEMAXANIB; SILDENAFIL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY MEDIA; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME ACTIVATION; ENZYME INHIBITION; HEART OUTPUT; HEART RIGHT VENTRICLE FUNCTION; HEART RIGHT VENTRICLE HYPERTROPHY; HEART RIGHT VENTRICLE PERFORMANCE; HEART RIGHT VENTRICLE PRESSURE; HYPOXIA; LUNG HEMODYNAMICS; LUNG RESISTANCE; MALE; NEOINTIMA; NONHUMAN; PULMONARY HYPERTENSION; RAT; SIGNAL TRANSDUCTION; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TREATMENT RESPONSE;

ANIMALS; ANOXIA; APOPTOSIS; BLOOD PRESSURE; BLOTTING, WESTERN; CASPASE 3; CELL PROLIFERATION; CYCLIC GMP; GUANYLATE CYCLASE; HEMODYNAMICS; HYPERTENSION, PULMONARY; HYPERTROPHY, RIGHT VENTRICULAR; IMMUNOHISTOCHEMISTRY; INDOLES; LUNG; MALE; NITRIC OXIDE SYNTHASE TYPE III; PHOSPHODIESTERASE 5 INHIBITORS; PIPERAZINES; PURINES; PYRAZOLES; PYRIMIDINES; PYRROLES; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, CYTOPLASMIC AND NUCLEAR; SULFONES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84865065450     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0043433     Document Type: Article

References (42)

1. Schermuly RT, Ghofrani HA, Wilkins MR, Grimminger F, (2011) Mechanisms of disease: pulmonary arterial hypertension. Nat Rev Cardiol 8: 443-455.
2. Morrell NW, Adnot S, Archer SL, Dupuis J, Jones PL, et al. (2009) Cellular and molecular basis of pulmonary arterial hypertension. J Am Coll Cardiol 54: S20-31.
3. Arnold WP, Mittal CK, Katsuki S, Murad F, (1977) Nitric oxide activates guanylate cyclase and increases guanosine 3′:5′-cyclic monophosphate levels in various tissue preparations. Proc Natl Acad Sci U S A 74: 3203-3207.
4. Galie N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, et al. (2005) Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 353: 2148-2157.
5. Michelakis ED, McMurtry MS, Sonnenberg B, Archer SL, (2003) The NO-K+ channel axis in pulmonary arterial hypertension. Activation by experimental oral therapies. Adv Exp Med Biol 543: 293-322.
6. Stasch JP, Hobbs AJ, (2009) NO-independent, haem-dependent soluble guanylate cyclase stimulators. Handb Exp Pharmacol 191: 277-308.
7. Evgenov OV, Ichinose F, Evgenov NV, Gnoth MJ, Falkowski GE, et al. (2004) Soluble guanylate cyclase activator reverses acute pulmonary hypertension and augments the pulmonary vasodilator response to inhaled nitric oxide in awake lambs. Circulation 110: 2253-2259.
8. Dumitrascu R, Weissmann N, Ghofrani HA, Dony E, Beuerlein K, et al. (2006) Activation of soluble guanylate cyclase reverses experimental pulmonary hypertension and vascular remodeling. Circulation 113: 286-295.
9. Ghofrani HA, Hoeper MM, Halank M, Meyer FJ, Staehler G, et al. (2010) Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: a phase II study. Eur Respir J 36: 792-799.
10. Schermuly RT, Kreisselmeier KP, Ghofrani HA, Samidurai A, Pullamsetti S, et al. (2004) Antiremodeling effects of iloprost and the dual-selective phosphodiesterase 3/4 inhibitor tolafentrine in chronic experimental pulmonary hypertension. Circ Res 94: 1101-1108.
11. Bauer NR, Moore TM, McMurtry IF, (2007) Rodent models of PAH: are we there yet? Am J Physiol Lung Cell Mol Physiol 293: L580-582.
12. Stenmark KR, Meyrick B, Galie N, Mooi WJ, McMurtry IF, (2009) Animal models of pulmonary arterial hypertension: the hope for etiological discovery and pharmacological cure. Am J Physiol Lung Cell Mol Physiol 297: L1013-1032.
13. Taraseviciene-Stewart L, Kasahara Y, Alger L, Hirth P, Mc Mahon G, et al. (2001) Inhibition of the VEGF receptor 2 combined with chronic hypoxia causes cell death-dependent pulmonary endothelial cell proliferation and severe pulmonary hypertension. FASEB J 15: 427-438.
14. Oka M, Homma N, Taraseviciene-Stewart L, Morris KG, Kraskauskas D, et al. (2007) Rho kinase-mediated vasoconstriction is important in severe occlusive pulmonary arterial hypertension in rats. Circ Res 100: 923-929.
15. Abe K, Toba M, Alzoubi A, Ito M, Fagan KA, et al. (2010) Formation of plexiform lesions in experimental severe pulmonary arterial hypertension. Circulation 121: 2747-2754.
16. Taraseviciene-Stewart L, Scerbavicius R, Choe KH, Cool C, Wood K, et al. (2006) Simvastatin causes endothelial cell apoptosis and attenuates severe pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 291: L668-676.
17. Schermuly RT, Dony E, Ghofrani HA, Pullamsetti S, Savai R, et al. (2005) Reversal of experimental pulmonary hypertension by PDGF inhibition. J Clin Invest 115: 2811-2821.
18. Tei C, Ling LH, Hodge DO, Bailey KR, Oh JK, et al. (1995) New index of combined systolic and diastolic myocardial performance: a simple and reproducible measure of cardiac function - a study in normals and dilated cardiomyopathy. J Cardiol 26: 357-366.
19. Kosanovic D, Kojonazarov B, Luitel H, Dahal BK, Sydykov A, et al. (2011) Therapeutic efficacy of TBC3711 in monocrotaline-induced pulmonary hypertension. Respir Res 12: 87.
20. Urboniene D, Haber I, Fang YH, Thenappan T, Archer SL, (2010) Validation of high-resolution echocardiography and magnetic resonance imaging vs. high-fidelity catheterization in experimental pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 299: L401-412.
21. Schermuly RT, Stasch JP, Pullamsetti SS, Middendorff R, Muller D, et al. (2008) Expression and function of soluble guanylate cyclase in pulmonary arterial hypertension. Eur Respir J 32: 881-891.
22. Dahal BK, Kosanovic D, Pamarthi PK, Sydykov A, Lai YJ, et al. (2010) Therapeutic efficacy of azaindole-1 in experimental pulmonary hypertension. Eur Respir J 36: 808-818.
23. Bogaard HJ, Mizuno S, Guignabert C, Al Hussaini AA, Farkas D, et al. (2012) Copper-dependence of angioproliferation in pulmonary arterial hypertension in rats and humans. Am J Respir Cell Mol Biol 46: 582-591.
24. Stasch JP, Schmidt PM, Nedvetsky PI, Nedvetskaya TY, H SA, et al. (2006) Targeting the heme-oxidized nitric oxide receptor for selective vasodilatation of diseased blood vessels. J Clin Invest 116: 2552-2561.
25. Fagan KA, Tyler RC, Sato K, Fouty BW, Morris KG Jr, et al. (1999) Relative contributions of endothelial, inducible, and neuronal NOS to tone in the murine pulmonary circulation. Am J Physiol 277: L472-478.
26. Ghofrani HA, Pepke-Zaba J, Barbera JA, Channick R, Keogh AM, et al. (2004) Nitric oxide pathway and phosphodiesterase inhibitors in pulmonary arterial hypertension. J Am Coll Cardiol 43: 68S-72S.
27. Li D, Zhou N, Johns RA, (1999) Soluble guanylate cyclase gene expression and localization in rat lung after exposure to hypoxia. Am J Physiol 277: L841-847.
28. Li D, Laubach VE, Johns RA, (2001) Upregulation of lung soluble guanylate cyclase during chronic hypoxia is prevented by deletion of eNOS. Am J Physiol Lung Cell Mol Physiol 281: L369-376.
29. Maclean MR, Johnston ED, McCulloch KM, Pooley L, Houslay MD, et al. (1997) Phosphodiesterase isoforms in the pulmonary arterial circulation of the rat: changes in pulmonary hypertension. J Pharmacol Exp Ther 283: 619-624.
30. Black SM, Sanchez LS, Mata-Greenwood E, Bekker JM, Steinhorn RH, et al. (2001) sGC and PDE5 are elevated in lambs with increased pulmonary blood flow and pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 281: L1051-1057.
31. Wharton J, Strange JW, Moller GM, Growcott EJ, Ren X, et al. (2005) Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells. Am J Respir Crit Care Med 172: 105-113.
32. Bhatia S, Frantz RP, Severson CJ, Durst LA, McGoon MD, (2003) Immediate and long-term hemodynamic and clinical effects of sildenafil in patients with pulmonary arterial hypertension receiving vasodilator therapy. Mayo Clin Proc 78: 1207-1213.
33. Chockalingam A, Gnanavelu G, Venkatesan S, Elangovan S, Jagannathan V, et al. (2005) Efficacy and optimal dose of sildenafil in primary pulmonary hypertension. Int J Cardiol 99: 91-95.
34. Mittendorf J, Weigand S, Alonso-Alija C, Bischoff E, Feurer A, et al. (2009) Discovery of riociguat (BAY 63-2521): a potent, oral stimulator of soluble guanylate cyclase for the treatment of pulmonary hypertension. ChemMedChem 4: 853-865.
35. Kitabatake A, Inoue M, Asao M, Masuyama T, Tanouchi J, et al. (1983) Noninvasive evaluation of pulmonary hypertension by a pulsed Doppler technique. Circulation 68: 302-309.
36. D'Alonzo GE, Barst RJ, Ayres SM, Bergofsky EH, Brundage BH, et al. (1991) Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 115: 343-349.
37. Grimminger F, Weimann G, Frey R, Voswinckel R, Thamm M, et al. (2009) First acute haemodynamic study of soluble guanylate cyclase stimulator riociguat in pulmonary hypertension. Eur Respir J 33: 785-792.
38. Schermuly RT, Kreisselmeier KP, Ghofrani HA, Yilmaz H, Butrous G, et al. (2004) Chronic sildenafil treatment inhibits monocrotaline-induced pulmonary hypertension in rats. Am J Respir Crit Care Med 169: 39-45.
39. Nagendran J, Archer SL, Soliman D, Gurtu V, Moudgil R, et al. (2007) Phosphodiesterase type 5 is highly expressed in the hypertrophied human right ventricle, and acute inhibition of phosphodiesterase type 5 improves contractility. Circulation 116: 238-248.
40. Sharkovska Y, Kalk P, Lawrenz B, Godes M, Hoffmann LS,et al. Nitric oxide-independent stimulation of soluble guanylate cyclase reduces organ damage in experimental low-renin and high-renin models. J Hypertens 28: 1666-1675.
41. Geschka S, Kretschmer A, Sharkovska Y, Evgenov OV, Lawrenz B,et al. Soluble guanylate cyclase stimulation prevents fibrotic tissue remodeling and improves survival in salt-sensitive Dahl rats. PLoS One 6: e21853.
42. Schymura Y, Janssen W, Wietelmann A, Stasch JP, Weissmann N, et al. (2011) Effects Of BAY 41-8543 and sildenafil on right heart structure and function in pulmonary artery banded mice. Am J Respir Crit Care Med 183: A5007.